Skeletal health in adults with HIV infection. (Q38204540)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24731663 AND SRC:MED&resulttype=core&format=json

14 March 2020

title

Skeletal health in adults with HIV infection (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24731663 AND SRC:MED&resulttype=core&format=json

14 March 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24731663 AND SRC:MED&resulttype=core&format=json

14 March 2020

Ian Reid

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24731663 AND SRC:MED&resulttype=core&format=json

14 March 2020

author name string

Andrew Grey

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24731663 AND SRC:MED&resulttype=core&format=json

14 March 2020

publication date

26 February 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24731663 AND SRC:MED&resulttype=core&format=json

The Lancet: Diabetes & Endocrinology

14 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24731663 AND SRC:MED&resulttype=core&format=json

14 March 2020

volume

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24731663 AND SRC:MED&resulttype=core&format=json

14 March 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24731663 AND SRC:MED&resulttype=core&format=json

14 March 2020

page(s)

63-74

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24731663 AND SRC:MED&resulttype=core&format=json

Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. Multicenter AIDS Cohort Study Investigators.

14 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1016/S2213-8587(13)70181-5

7 January 2021

Quality of life outcomes of combination zalcitabine-zidovudine, saquinavir-zidovudine, and saquinavir-zalcitabine-zidovudine therapy for HIV-infected adults with CD4 cell counts between 50 and 350 per cubic millimeter. PISCES (SV14604) Study Group

1 reference

https://api.crossref.org/works/10.1016/S2213-8587(13)70181-5

7 January 2021

Changes in the uptake of antiretroviral therapy and survival in people with known duration of HIV infection in Europe: results from CASCADE.

1 reference

https://api.crossref.org/works/10.1016/S2213-8587(13)70181-5

7 January 2021

Life expectancy of recently diagnosed asymptomatic HIV-infected patients approaches that of uninfected individuals

1 reference

https://api.crossref.org/works/10.1016/S2213-8587(13)70181-5

7 January 2021

Alterations in bone turnover in HIV-positive patients

1 reference

https://api.crossref.org/works/10.1016/S2213-8587(13)70181-5

7 January 2021

Bone remodelling in human immunodeficiency virus-1-infected patients. A histomorphometric study

1 reference

https://api.crossref.org/works/10.1016/S2213-8587(13)70181-5

7 January 2021

Bone mineral density in patients with human immunodeficiency virus infection

1 reference

https://api.crossref.org/works/10.1016/S2213-8587(13)70181-5

7 January 2021

Changes in calciotropic hormones and biochemical markers of bone metabolism in patients with human immunodeficiency virus infection

1 reference

https://api.crossref.org/works/10.1016/S2213-8587(13)70181-5

7 January 2021

Osteopenia in HIV-infected women prior to highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016/S2213-8587(13)70181-5

7 January 2021

Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016/S2213-8587(13)70181-5

7 January 2021

Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review

1 reference

https://api.crossref.org/works/10.1016/S2213-8587(13)70181-5

7 January 2021

Bone mineral density is not reduced in HIV-infected Caucasian men treated with highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016/S2213-8587(13)70181-5

7 January 2021

CLINICAL Review # : low body weight mediates the relationship between HIV infection and low bone mineral density: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016/S2213-8587(13)70181-5

7 January 2021

Bone mineral density in human immunodeficiency virus-1 infected men with hypogonadism prior to highly-active-antiretroviral-therapy (HAART).

1 reference

https://api.crossref.org/works/10.1016/S2213-8587(13)70181-5

7 January 2021

Low bone mass and high bone turnover in postmenopausal human immunodeficiency virus-infected women

1 reference

https://api.crossref.org/works/10.1016/S2213-8587(13)70181-5

7 January 2021

Short-term bone loss in HIV-infected premenopausal women

1 reference

https://api.crossref.org/works/10.1016/S2213-8587(13)70181-5

7 January 2021

Low bone mass in behaviorally HIV-infected young men on antiretroviral therapy: Adolescent Trials Network Study 021B.

1 reference

https://api.crossref.org/works/10.1016/S2213-8587(13)70181-5

7 January 2021

The combination of FRAX and Ageing Male Symptoms scale better identifies treated HIV males at risk for major fracture

1 reference

https://api.crossref.org/works/10.1016/S2213-8587(13)70181-5

7 January 2021

Low bone mineral density, regardless of HIV status, in men who have sex with men.

1 reference

https://api.crossref.org/works/10.1016/S2213-8587(13)70181-5

7 January 2021

Osteopenia in HIV-infected patients: is it the disease or is it the treatment?

1 reference

https://api.crossref.org/works/10.1016/S2213-8587(13)70181-5

7 January 2021

BMD Is Reduced in HIV-Infected Men Irrespective of Treatment

1 reference

https://api.crossref.org/works/10.1016/S2213-8587(13)70181-5

7 January 2021

Decreased bone mineral density and increased fracture risk in aging men with or at risk for HIV infection

1 reference

https://api.crossref.org/works/10.1016/S2213-8587(13)70181-5

7 January 2021

Fragility fractures and bone mineral density in HIV positive women: a case-control population-based study

1 reference

https://api.crossref.org/works/10.1016/S2213-8587(13)70181-5

7 January 2021

Relationships among body mass, its components, and bone

1 reference

https://api.crossref.org/works/10.1016/S2213-8587(13)70181-5

7 January 2021

Body mass index is not a good predictor of bone density: results from WHI, CHS, and EPIDOS.

1 reference

https://api.crossref.org/works/10.1016/S2213-8587(13)70181-5

7 January 2021

Impact of HIV infection on total body composition in treatment-naive men evaluated by dual-energy X-ray absorptiometry comparison of 90 untreated HIV-infected men to 241 controls

1 reference

https://api.crossref.org/works/10.1016/S2213-8587(13)70181-5

7 January 2021

Effects of weight, body composition, and testosterone on bone mineral density in HIV-infected women

1 reference

https://api.crossref.org/works/10.1016/S2213-8587(13)70181-5

7 January 2021

Association of regional body composition with bone mineral density in HIV-infected and HIV-uninfected women: women's interagency HIV study

1 reference

https://api.crossref.org/works/10.1016/S2213-8587(13)70181-5

7 January 2021

Body composition, soluble markers of inflammation, and bone mineral density in antiretroviral therapy-naive HIV-1-infected individuals

1 reference

https://api.crossref.org/works/10.1016/S2213-8587(13)70181-5

7 January 2021

Bone mineral density in HIV-negative men participating in a tenofovir pre-exposure prophylaxis randomized clinical trial in San Francisco

1 reference

https://api.crossref.org/works/10.1016/S2213-8587(13)70181-5

7 January 2021

Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana

1 reference

https://api.crossref.org/works/10.1016/S2213-8587(13)70181-5

7 January 2021

High prevalence of reduced bone mineral density in primary HIV-1-infected men

1 reference

https://api.crossref.org/works/10.1016/S2213-8587(13)70181-5

7 January 2021

HIV infection--a risk factor for osteoporosis

1 reference

https://api.crossref.org/works/10.1016/S2213-8587(13)70181-5

7 January 2021

Metabolic bone disease in HIV infection

1 reference

https://api.crossref.org/works/10.1016/S2213-8587(13)70181-5

7 January 2021

Physiologic frailty and fragility fracture in HIV-infected male veterans

1 reference

https://api.crossref.org/works/10.1016/S2213-8587(13)70181-5

7 January 2021

Stable bone density in HAART-treated individuals with HIV: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016/S2213-8587(13)70181-5

7 January 2021

Longitudinal analysis of bone density in human immunodeficiency virus-infected women

1 reference

https://api.crossref.org/works/10.1016/S2213-8587(13)70181-5

7 January 2021

Bone mineral density remains stable in HAART-treated HIV-infected men over 2 years

1 reference

https://api.crossref.org/works/10.1016/S2213-8587(13)70181-5

7 January 2021

The safety and efficacy of tenofovir DF in combination with lamivudine and efavirenz through 6 years in antiretroviral-naïve HIV-1-infected patients

1 reference

https://api.crossref.org/works/10.1016/S2213-8587(13)70181-5

7 January 2021

Stable bone mineral density over 6 years in HIV-infected men treated with highly active antiretroviral therapy (HAART)

1 reference

https://api.crossref.org/works/10.1016/S2213-8587(13)70181-5

7 January 2021

Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial

1 reference

https://api.crossref.org/works/10.1016/S2213-8587(13)70181-5

7 January 2021

Loss of bone mineral density after antiretroviral therapy initiation, independent of antiretroviral regimen.

1 reference

https://api.crossref.org/works/10.1016/S2213-8587(13)70181-5

7 January 2021

First line zidovudine/lamivudine/lopinavir/ritonavir leads to greater bone loss compared to nevirapine/lopinavir/ritonavir.

1 reference

https://api.crossref.org/works/10.1016/S2213-8587(13)70181-5

7 January 2021

Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study

1 reference

https://api.crossref.org/works/10.1016/S2213-8587(13)70181-5

7 January 2021

Prospective one-year bone loss in treatment-naïve HIV men and women on single or multiple drug HIV therapies

1 reference

https://api.crossref.org/works/10.1016/S2213-8587(13)70181-5

7 January 2021

Bone mineral density changes in protease inhibitor-sparing vs. nucleoside reverse transcriptase inhibitor-sparing highly active antiretroviral therapy: data from a randomized trial

1 reference

https://api.crossref.org/works/10.1016/S2213-8587(13)70181-5

7 January 2021

Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group A5224s, a substudy o

1 reference

https://api.crossref.org/works/10.1016/S2213-8587(13)70181-5

7 January 2021

Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: the MITOX Extension Study

1 reference

https://api.crossref.org/works/10.1016/S2213-8587(13)70181-5

7 January 2021

Improvement in lipoatrophy associated with highly active antiretroviral therapy in human immunodeficiency virus-infected patients switched from stavudine to abacavir or zidovudine: the results of the TARHEEL study

1 reference

https://api.crossref.org/works/10.1016/S2213-8587(13)70181-5

7 January 2021

Switching to a protease inhibitor-containing, nucleoside-sparing regimen (lopinavir/ritonavir plus efavirenz) increases limb fat but raises serum lipid levels: results of a prospective randomized trial (AIDS clinical trial group 5125s).

1 reference

https://api.crossref.org/works/10.1016/S2213-8587(13)70181-5

7 January 2021

Effect of reducing the dose of stavudine on body composition, bone density, and markers of mitochondrial toxicity in HIV-infected subjects: a randomized, controlled study

1 reference

https://api.crossref.org/works/10.1016/S2213-8587(13)70181-5

7 January 2021

A simplification trial switching from nucleoside reverse transcriptase inhibitors to once-daily fixed-dose abacavir/lamivudine or tenofovir/emtricitabine in HIV-1-infected patients with virological suppression.

1 reference

https://api.crossref.org/works/10.1016/S2213-8587(13)70181-5

7 January 2021

Simplification of antiretroviral therapy with tenofovir-emtricitabine or abacavir-Lamivudine: a randomized, 96-week trial

1 reference

https://api.crossref.org/works/10.1016/S2213-8587(13)70181-5

7 January 2021

Body composition changes after switching from protease inhibitors to raltegravir

1 reference

https://api.crossref.org/works/10.1016/S2213-8587(13)70181-5

7 January 2021

Mitochondrial function, inflammation, fat and bone in HIV lipoatrophy: randomized study of uridine supplementation or switch to tenofovir.

1 reference

https://api.crossref.org/works/10.1016/S2213-8587(13)70181-5

7 January 2021

A switch in therapy to a reverse transcriptase inhibitor sparing combination of lopinavir/ritonavir and raltegravir in virologically suppressed HIV-infected patients: a pilot randomized trial to assess efficacy and safety profile: the KITE study

1 reference

https://api.crossref.org/works/10.1016/S2213-8587(13)70181-5

7 January 2021

Comparison of bone and renal effects in HIV-infected adults switching to abacavir or tenofovir based therapy in a randomized trial

1 reference

https://api.crossref.org/works/10.1016/S2213-8587(13)70181-5

7 January 2021

Impact of Switching From Zidovudine to Tenofovir Disoproxil Fumarate on Bone Mineral Density and Markers of Bone Metabolism in Virologically Suppressed HIV-1 Infected Patients; A Substudy of the PREPARE Study

1 reference

https://api.crossref.org/works/10.1016/S2213-8587(13)70181-5

7 January 2021

Impact of switching from zidovudine/lamivudine to tenofovir/emtricitabine on lipoatrophy: the RECOMB study.

1 reference

https://api.crossref.org/works/10.1016/S2213-8587(13)70181-5

7 January 2021

Antiretroviral preexposure prophylaxis for HIV prevention

1 reference

https://api.crossref.org/works/10.1016/S2213-8587(13)70181-5

7 January 2021

Fanconi's syndrome in HIV adults: report of three cases and literature review

1 reference

https://api.crossref.org/works/10.1016/S2213-8587(13)70181-5

7 January 2021

Continuous antiretroviral therapy decreases bone mineral density

1 reference

https://api.crossref.org/works/10.1016/S2213-8587(13)70181-5

7 January 2021

Interruption or deferral of antiretroviral therapy reduces markers of bone turnover compared with continuous therapy: The SMART body composition substudy

1 reference

https://api.crossref.org/works/10.1016/S2213-8587(13)70181-5

7 January 2021

Prospective evaluation of bone markers, parathormone and 1,25-(OH)₂ vitamin D in HIV-positive patients after the initiation of tenofovir/emtricitabine with atazanavir/ritonavir or efavirenz

1 reference

https://api.crossref.org/works/10.1016/S2213-8587(13)70181-5

7 January 2021

Longitudinal evolution of bone mineral density and bone markers in human immunodeficiency virus-infected individuals.

1 reference

https://api.crossref.org/works/10.1016/S2213-8587(13)70181-5

7 January 2021

Changes in bone turnover and bone loss in HIV-infected patients changing treatment to tenofovir-emtricitabine or abacavir-lamivudine

1 reference

https://api.crossref.org/works/10.1016/S2213-8587(13)70181-5

7 January 2021

Bone disease and HIV infection

1 reference

https://api.crossref.org/works/10.1016/S2213-8587(13)70181-5

7 January 2021

Alterations in the immuno-skeletal interface drive bone destruction in HIV-1 transgenic rats

1 reference

https://api.crossref.org/works/10.1016/S2213-8587(13)70181-5

7 January 2021

An HIV-1 transgenic rat that develops HIV-related pathology and immunologic dysfunction

1 reference

https://api.crossref.org/works/10.1016/S2213-8587(13)70181-5

7 January 2021

Fracture incidence in HIV-infected women: results from the Women's Interagency HIV Study

1 reference

https://api.crossref.org/works/10.1016/S2213-8587(13)70181-5

7 January 2021

Ten-year incidence and risk factors of bone fractures in a cohort of treated HIV1-infected adults

1 reference

https://api.crossref.org/works/10.1016/S2213-8587(13)70181-5

7 January 2021

Increased Rates of Bone Fracture Among HIV-Infected Persons in the HIV Outpatient Study (HOPS) Compared With the US General Population, 2000-2006

1 reference

https://api.crossref.org/works/10.1016/S2213-8587(13)70181-5

7 January 2021

Fractures after antiretroviral initiation

1 reference

https://api.crossref.org/works/10.1016/S2213-8587(13)70181-5

7 January 2021

Fracture prevalence among human immunodeficiency virus (HIV)-infected versus non-HIV-infected patients in a large U.S. healthcare system

1 reference

https://api.crossref.org/works/10.1016/S2213-8587(13)70181-5

7 January 2021

Increased risk of fragility fractures among HIV infected compared to uninfected male veterans

1 reference

https://api.crossref.org/works/10.1016/S2213-8587(13)70181-5

7 January 2021

Incidence of low and high-energy fractures in persons with and without HIV infection: a Danish population-based cohort study

1 reference

https://api.crossref.org/works/10.1016/S2213-8587(13)70181-5

7 January 2021

Risk of hip fracture associated with hepatitis C virus infection and hepatitis C/human immunodeficiency virus coinfection

1 reference

https://api.crossref.org/works/10.1016/S2213-8587(13)70181-5

7 January 2021

HIV infection is strongly associated with hip fracture risk, independently of age, gender, and comorbidities: a population-based cohort study

1 reference

https://api.crossref.org/works/10.1016/S2213-8587(13)70181-5

7 January 2021

Importance of events per independent variable in proportional hazards regression analysis. II. Accuracy and precision of regression estimates

1 reference

https://api.crossref.org/works/10.1016/S2213-8587(13)70181-5

7 January 2021

Osteoporotic fracture risk associated with cumulative exposure to tenofovir and other antiretroviral agents

1 reference

https://api.crossref.org/works/10.1016/S2213-8587(13)70181-5

7 January 2021

Low CD4 count is associated with an increased risk of fragility fracture in HIV-infected patients

1 reference

https://api.crossref.org/works/10.1016/S2213-8587(13)70181-5

7 January 2021

Overall benefit of antiretroviral treatment on the risk of fracture in HIV

1 reference

https://api.crossref.org/works/10.1016/S2213-8587(13)70181-5

7 January 2021

Biodemographic comparisons of homosexual and heterosexual men in the Kinsey Interview Data

1 reference

https://api.crossref.org/works/10.1016/S2213-8587(13)70181-5

7 January 2021

The influence of sexual orientation on body dissatisfaction in adult men and women.

1 reference

https://api.crossref.org/works/10.1016/S2213-8587(13)70181-5

7 January 2021

Smoking among lesbians, gays, and bisexuals: a review of the literature

1 reference

https://api.crossref.org/works/10.1016/S2213-8587(13)70181-5

7 January 2021

Drug use and other risk factors related to lower body mass index among HIV-infected individuals

1 reference

https://api.crossref.org/works/10.1016/S2213-8587(13)70181-5

7 January 2021

Circulating levels of inflammatory markers predict change in bone mineral density and resorption in older adults: a longitudinal study

1 reference

https://api.crossref.org/works/10.1016/S2213-8587(13)70181-5

7 January 2021

American Association of Clinical Endocrinologists medical guidelines for clinical practice for the prevention and treatment of postmenopausal osteoporosis: 2001 edition, with selected updates for 2003.

1 reference

https://api.crossref.org/works/10.1016/S2213-8587(13)70181-5

7 January 2021

A revised clinician's guide to the prevention and treatment of osteoporosis

1 reference

https://api.crossref.org/works/10.1016/S2213-8587(13)70181-5

7 January 2021

Case finding for the management of osteoporosis with FRAX--assessment and intervention thresholds for the UK.

1 reference

https://api.crossref.org/works/10.1016/S2213-8587(13)70181-5

7 January 2021

Construction and validation of a simplified fracture risk assessment tool for Canadian women and men: results from the CaMos and Manitoba cohorts.

1 reference

https://api.crossref.org/works/10.1016/S2213-8587(13)70181-5

7 January 2021

Differing perceptions of intervention thresholds for fracture risk: a survey of patients and doctors

1 reference

https://api.crossref.org/works/10.1016/S2213-8587(13)70181-5

7 January 2021

Bone-density testing interval and transition to osteoporosis in older women

1 reference

https://api.crossref.org/works/10.1016/S2213-8587(13)70181-5

7 January 2021

Bone disease in HIV infection: a practical review and recommendations for HIV care providers

1 reference

https://api.crossref.org/works/10.1016/S2213-8587(13)70181-5

7 January 2021

Continuing bisphosphonate treatment for osteoporosis--for whom and for how long?

1 reference

https://api.crossref.org/works/10.1016/S2213-8587(13)70181-5

7 January 2021

Alendronate reduces bone resorption in HIV-associated osteopenia/osteoporosis.

1 reference

https://api.crossref.org/works/10.1016/S2213-8587(13)70181-5

7 January 2021

Alendronate, vitamin D, and calcium for the treatment of osteopenia/osteoporosis associated with HIV infection

1 reference

https://api.crossref.org/works/10.1016/S2213-8587(13)70181-5

7 January 2021

Alendronate with calcium and vitamin D supplementation is safe and effective for the treatment of decreased bone mineral density in HIV.

1 reference

https://api.crossref.org/works/10.1016/S2213-8587(13)70181-5

7 January 2021

Effect of Alendronate on HIV-Associated Osteoporosis: A Randomized, Double-Blind, Placebo-Controlled, 96-Week Trial (ANRS 120)

1 reference

https://api.crossref.org/works/10.1016/S2213-8587(13)70181-5

7 January 2021

Annual zoledronate increases bone density in highly active antiretroviral therapy-treated human immunodeficiency virus-infected men: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016/S2213-8587(13)70181-5

7 January 2021

A double-blinded, randomized controlled trial of zoledronate therapy for HIV-associated osteopenia and osteoporosis

1 reference

https://api.crossref.org/works/10.1016/S2213-8587(13)70181-5

7 January 2021

Effects of intravenous zoledronate on bone turnover and BMD persist for at least 24 months

1 reference

https://api.crossref.org/works/10.1016/S2213-8587(13)70181-5

7 January 2021

Effects of intravenous zoledronate on bone turnover and bone density persist for at least five years in HIV-infected men.

1 reference

https://api.crossref.org/works/10.1016/S2213-8587(13)70181-5

7 January 2021

Reduced bone mineral density in human immunodeficiency virus-infected patients and its association with increased central adiposity and postload hyperglycemia

1 reference

https://api.crossref.org/works/10.1016/S2213-8587(13)70181-5

7 January 2021

Total body composition by DXA of 241 HIV-negative men and 162 HIV-infected men: proposal of reference values for defining lipodystrophy

1 reference

https://api.crossref.org/works/10.1016/S2213-8587(13)70181-5

7 January 2021

HIV infection and bone mineral density in middle-aged women

1 reference

https://api.crossref.org/works/10.1016/S2213-8587(13)70181-5

7 January 2021